Long induction of tolerance to imatinib.
BMJ Case Rep
; 13(12)2020 Dec 13.
Article
em En
| MEDLINE
| ID: mdl-33318243
ABSTRACT
Imatinib is used to treat several haematological and solid malignancies. Cutaneous side effects could often limit the use of this medication. We present a case of a 62-year-old woman with a history of a gastrointestinal stromal tumour that developed a delayed cutaneous adverse reaction 10 days after starting imatinib 400 mg daily. She developed the same symptoms with reintroduction at a dose of 100 mg and with an alternative tyrosine kinase inhibitor, nilotinib 50 mg/day. Given that imatinib was considered her best treatment, she underwent a long induction of drug tolerance (IDT) protocol to imatinib. Patient tolerated the medication without further reactions for 6 months and had improvement of her cancer per last imaging studies. IDT should be considered in delayed hypersensitivity reactions to imatinib after a failed reintroduction of the drug or when no other equally effective agents are available.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Tumores do Estroma Gastrointestinal
/
Tolerância a Medicamentos
/
Mesilato de Imatinib
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
/
Guideline
Limite:
Female
/
Humans
/
Middle aged
Idioma:
En
Revista:
BMJ Case Rep
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Estados Unidos